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Summary
Pax2 is a transcription factor with important functions
during kidney development [1–3]. Ectopic expression
of Pax2 in podocytes has been reported in various glo-
merular diseases [4–7], but the functional relevance
remains unknown. We developed an inducible mouse
model that allows activation of Pax2 specifically in po-
docytes. Persistent expression of Pax2 did not inter-
fere with the initial differentiation of podocytes, but
mice ectopically expressing PAX2 developed end-
stage renal failure soon after birth. Similarly, activa-
tion of PAX2 in healthy adult animals resulted in renal
disease within 3 weeks after podocyte-specific induc-
tion of a deleter Cre. PAX2 activation caused repres-
sion of the podocyte key regulator molecule Wt1 and
consequently a dramatic reduction of nephrin expres-
sion. Recruitment of the groucho-related protein TLE4
may be involved in converting Pax2 into a transcrip-
tional repressor of Wt1. Finally, treatment of mice
with an angiotensin-converting enzyme (ACE) inhibi-
tor normalized renal function and induced upregula-
tion of the important structural molecule nephrin via
a Wt1-independent pathway. Our data demonstrate
the functional significance of PAX2 reexpression in
mature podocytes for the development of glomerular
diseases and suggest that reactivation of PAX genes
in terminally differentiated cells leads to a more dedif-
ferentiated phenotype.
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PAX2 encodes a transcriptional regulator with essential
functions during kidney development [1, 2]. After com-
pletion of development, PAX2 expression in the kidney
is restricted to a minority of epithelial cells [3]. Under
pathological conditions, e.g., juvenile nephronophtisis
[4], cystic and hyperproliferative kidney epithelium [5],
focal segmental glomerulosclerosis [6], and collapsing
glomerulopathy, which occurs mostly as HIV-associated
nephropathy (HIVAN) [7], ectopic PAX2 expression in
glomerular podocytes is a common finding. However,
the functional consequence of PAX2 expression in glo-
merular diseases is not well understood. Thus, we
directed the expression of this gene to the adult glomer-
ular podocyte by means of a yeast artificial chromosome
(YAC) covering the human WT1 locus (Figure 1A) [8]. The
YAC was modified by inserting the mouse Pax2b cDNA
preceded by an IRES signal into WT1 exon2. To avoid
possible lethality due to ectopic Pax2 expression [9]
and to permit a controlled activation of the transgene,
we inserted a floxed b-geo cassette with a strong polya-
denylation signal [10] into intron1 of the WT1 locus that
acts as a marker and also as a STOP cassette, making
expression of Pax2 Cre dependent. Heterozygous (Z/
Pax2) mice generated with this construct showed a nor-
mal lifespan and fertility. LacZ staining demonstrated the
expression of the transgene in a WT1-specific pattern
during kidney development and at high levels in mature
glomerular podocytes (Figure 1B and data not shown).
To activate Pax2, we crossed Z/Pax2 mice with a Cre-de-
leter strain (Cred) [11], which expresses the CRE recom-
binase ubiquitously. Immunofluorescent analysis in dou-
ble heterozygous mice (Z/Pax2+/2;Cred) confirmed the
activation of Pax2 in developing glomeruli (Figure 1C,
part d). Ectopic expression of Pax2 under control of
WT1 regulatory regions did not interfere with embryo-
genesis, and the embryonic kidney developed normally
(data not shown). Electron microscopic analysis at em-
bryonic day 16.5 (E16.5) revealed an identical glomerular
development in double heterozygous mice and in con-
trols (Figure 1D, parts a and b). The more mature juxta-
medullary glomeruli in double heterozygous mice pos-
sessed all glomerular cell types and were in the
process of forming a normal filtration structure. They dis-
played groups of foot processes separated by a slit
diaphragm, a glomerular basement membrane, and an
endothelium with moderate fenestration. Perinatally,
double transgenic mice developed quickly severe pro-
teinuria and died within 5 days after birth, most probably
due to renal failure. Histological analysis confirmed filtra-
tion defects with prominent protein casts in proximal tu-
bules and collecting ducts (Figure 1C, part e). Strikingly,
glomeruli of double transgenic animals showed a col-
lapse of the glomerular tuft (Figure 1C, part f), reminis-
cent of collapsing glomerulopathy in humans. Electron
microscopic analysis on days 1, 3, and 5 after birth
revealed a lower degree of podocyte interdigitation in
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794Figure 1. Construct Design and Analysis of
Mice Expressing Pax2 Ectopically in Glomer-
ular Podocytes
(A) Schematic drawing of the transgenic con-
struct. A 480 kb YAC covering the human
WT1 locus was used to provide WT1-specific
regulatory elements. Pax2b cDNA preceded
by an internal ribosomal entry site (IRES)
and followed by a SV40 polyadenylation sig-
nal was inserted into exon2 of the WT1 locus.
To provide control over transgene expres-
sion, a splice acceptor (SA)-IRES-b-galacto-
sidase neomycin fusion gene (b-geo) fol-
lowed by a polyadenylation signal and
flanked by loxP sites was inserted into in-
tron1. Ura3 and Leu2 represent selectable
markers for yeast targeting. loxP sites are
symbolized by black arrowheads. YAC trans-
genic animals were generated as described
[28].
(B) Detection of b-galactosidase expression
by lacZ staining of E18.5 mouse embryos
[29]. Note that the transgene is expressed in
a WT1-specific pattern with strong staining
in developing glomeruli.
(C) Immunostaining for Pax2 at E18.5 shows
strong staining in condensing blastema and
the collecting ducts (a). Double transgenic
animals (Z/Pax2;Cred) exhibit additional glo-
merular staining (arrows in d). Histological
(hematoxylin & eosin) analysis of control
and double transgenic animals after birth re-
vealed tubular protein casts and collapsed
glomeruli (e, f).
(D) Electron microscopic analysis of control
and double transgenic animals at E16.5 and
P5 [30]. Note the normal footprocess forma-
tion in double transgenic mice at E16.5 (b)
and the low number of foot processes of po-
docytes (P) and effacement of process inter-
digitations at P5. Scale bars equal 100 mm in
(B) and (C) and 1 mm in (D).
Pax2 and Glomerular Disease
795Figure 2. Histological Analysis of Double Transgenic Mice with and without Tamoxifen Induction
Inducible double transgenic mice (Z/Pax2;CreTx) were generated by crossing Z/Pax2 transgenic animals with tamoxifen-inducible Cre-deleter
mice [12]. Double transgenic offspring was identified by PCR by the following primers: YAC-F 50-ACTTCACTCGGGCCTTGATAG-30; YAC-B
50-GTGGAGAGTCAGACTTGAAAG-30; Cre-F 50-CGCAGAACCTGAAGATGTTCGCGA-30; Cre-B 50-GGATCATCAGCTACACCAGAGACG-30.
Tamoxifen induction was performed as described [12].
(A) Immunohistochemical staining with Pax2 antibodies reveals strong and specific expression in glomerular podocytes (b, c), whereas unin-
duced glomeruli are devoid of staining (a). Immunostaining was performed as described [31] with an anti-Pax2 antibody from rabbit (PRB-
276P, Covance).
(B) 3 weeks after induction, histological analysis revealed little changes with some shrinkage of the glomerular tuft (b). In contrast, kidneys
3 months after induction showed glomerular sclerosis and were fibrotic (c).
(C) Sirius red staining was performed according to manufacturer’s instruction. Note the increased collagen deposition (red) 3 months after Pax2
induction (b, c), but not after 3 weeks of induction (a). TUNEL analysis of kidneys from double transgenic mice (Z/Pax2;CreTx) 3 weeks and
3 months after tamoxifen induction (arrows indicate glomeruli) was performed as described [32]. Massive apoptosis could be detected mainly
in tubular cells but also in glomeruli 3 months after Pax2 induction (e, f). PCNA immunostaining (anti-PCNA antibody from mouse, sc-56, Santa
Cruz Biotechnology) revealed proliferation of podocytes 3 months after activation of the transgene (h, i), whereas no PCNA staining could be
detected 3 weeks after induction (g), suggesting that podocyte proliferation is a secondary event. Scale bars equal 100 mm.
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796Figure 3. Functional and Molecular Analyses in Tamoxifen-Inducible Animals and Controls
A) Urinary analysis demonstrates a dramatic increase in protein levels in double transgenic mice 3 weeks after tamoxifen induction (b) when com-
pared to uninduced animals (a). Note that tamoxifen injection in the absence of the CreTx transgene had no effect on protein excretion (b). For
measurement of urinary protein excretion, male mice were housed individually in metabolic cages (Techniplast, Italy), urine was collected over
24 hr, the volume was measured, and the protein concentration was determined with the Bio-Rad protein assay (Bio-Rad Laboratories,
Germany).
(B) Real-time RT-PCR analysis of molecular markers 3 weeks after tamoxifen induction in Z/Pax2;CreTx mice (white bars, n = 6) and controls (dou-
ble transgenic mice injected with vehicle and single Z/Pax2 transgenic animals injected with tamoxifen, black bars, n = 12) was performed as
described [31]. No statistically significant change could be detected for the proposed downstream targets of Pax2 Gdnf and Sfrp2. In contrast,
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797double transgenic mice compared to wild-type. Patho-
logical changes were most prominent in the oldest juxta-
medullary glomeruli located in the deep cortex (see
Figure S1 in the Supplemental Data available with this ar-
ticle online), although they were also apparent in younger
glomerular populations. Podocyte foot processes with
slit diaphragms were rare; almost the entire glomerular
basement membrane surface was covered by broad
cell processes with displaced cell junctions or by podo-
cyte cell bodies (Figure 1D, part c). In these glomeruli, the
low number of foot processes is indicative of dedifferen-
tiation and effacement of process interdigitation. Mid-
cortical glomeruli and several juxtamedullary glomeruli
were less affected (data not shown). The low number of
fully formed foot processes and slit diaphragms in these
glomeruli may be the result of dedifferentiation and/or re-
tarded differentiation. Interestingly, in several younger
developing glomeruli of the outer cortex, filtration struc-
tures with rows of foot processes were present, further
supporting the hypothesis that generally at least part of
the foot processes first form and then dedifferentiate
(data not shown). These results suggest that glomerular
differentiation is normal during embryonic development,
but at later stages dedifferentiation and pathological
transformation occurs. Besides the kidney abnormalities
described above, Z/Pax2+/2;Cred animals had smaller
gonads and spleens and a reduced number of white
blood cells, which may result from Pax2 expression
under WT1 regulatory sequences (Figure S2).
To test the value of our model for functional studies,
we examined whether ectopic expression of Pax2would
also cause glomerular disease when induced in adult
podocytes. For this purpose, we employed a tamoxi-
fen-inducible CRE line (CreTx) that shows predominant
expression in podocytes [12]. Pax2 expression could
be detected as early as 1 week after tamoxifen injection
in double transgenic mice and reached a plateau after 3
weeks (Figure 2A, parts b and c). To estimate the degree
of induction, double-immunofluorescent stainings for
synaptopodin to identify the glomeruli and Pax2 were
performed. Counting revealed that 95% 6 1.3% of the
glomeruli expressed Pax2 after 3 weeks of induction,
whereas no Pax2 expression in glomeruli could be de-
tected in uninduced controls (six optical fields from
three different animals each). Histological abnormalities
became apparent as early as 3 weeks after induction
and were characterized by mild shrinkage of the glo-
merular tuft and an increase of the glomerular space(Figure 2B, part b). By electron microscopy, podocytes
often showed microvillous transformation at the apical
cell membrane, indicative of initial stages of podocyte
deterioration (Figure S3A). A large number of proximal
tubules were also affected. In severely damaged tu-
bules, inclusion bodies containing electron-dense and
lamellated material were found, probably resulting
from protein accumulation (Figure S3B) [13]. By 3
months, glomeruli became focal segmental sclerotic
and tissues showed clear signs of fibrosis (Figure 2B,
part c), indicating that also focal segmental sclerosis,
which is accompanied by glomerular Pax2 expression
[6] in humans, might be due to prolonged Pax2 expres-
sion. Fibrosis was confirmed by collagen staining with
Sirius Red (Waldeck GmbH, Mu¨nster, Germany), which
was increased dramatically after 3 months (Figure 2C,
parts b and c) but not after 3 weeks (Figure 2C, part a).
Pax2 has been suggested to promote cellular prolifer-
ation [14], and podocytes of patients with glomerular
disease have been demonstrated to be positive for pro-
liferation markers such as PCNA [6]. In addition, in-
creased apoptosis in collapsing glomerulopathy [6]
and focal segmental glomerulosclerosis [13] has been
demonstrated. Analysis of our mouse model confirmed
increased apoptosis predominantly in tubular cells, but
also in the glomeruli (Figure 2C, parts e and f) 3 months
after tamoxifen injection. Increased proliferation of po-
docytes as assessed by immunostaining for PCNA oc-
curred 3 months after activation of the transgene (Fig-
ure 2C, parts h and i). In contrast, no PCNA staining
could be detected 3 weeks after induction, suggesting
that podocyte proliferation is a secondary rather than
a primary event (Figure 2C, part g) in the development
of glomerular diseases. These results were confirmed
by immunostaining for Ki-67 as a marker for proliferation
and cyclins D1/2 and E as indicators that the podocytes
reenter the cell cycle (data not shown). Proliferating cells
in the glomerulus were identified as podocytes by dou-
ble-staining with cyclin E and synaptopodin (Figure S4).
The histological findings were confirmed on a functional
level. Z/Pax2;CreTx mice developed 3 weeks after ta-
moxifen injection a significant proteinuria as a marker
for disturbed kidney function when compared to Z/
Pax2;CreTx animals injected with vehicle. A nonspecific
effect of tamoxifen administration could be excluded
since single Z/Pax2 transgenic mice injected in parallel
with the same dose of tamoxifen did not develop protei-
nurea (Figure 3A).the Wilms’ tumor suppressor geneWt1, its target nephrin, and the angiotensin receptorAT1Awere dramatically repressed. The following primers
were used for amplification: Gdnf, 50-GCTGTCTGCCTGGTGTTGCT-30 (forward primer), 50-TCTCTTCGAGGAAGCGCTGC-30 (reverse primer);
Sfrp2, 50-AGACATGCTGGAGTGCGACCGT-30 (forward primer), 50-CCAGGATGATCTTGGTGTCTCTGT-30 (reverse primer); Wt1, 50-AGAGC
CAGCCTACCATCCGCAA-30 (forward primer), 50-GGCTGCCTGTGCAACTGTCA-30 (reverse primer); Nephrin, 50-AGGGTCGGAGGAGGATC
GAA-30 (forward primer), 50-GGGAAGCTGGGGACTGAAGT-30 (reverse primer); Podocalyxin, 50-CCTCCAGGCCCCAGCA-30 (forward primer),
50-CCCAGCTTCATGTCACTGACT-30 (reverse primer); At1A, 50-AAGCCATCACCAGATCAAGTGC-30 (forward primer), 50-TGTAACTGTGCCTGC
CAGCC’ (reverse primer); Gapdh, 50-ATTCAACGGCACAGTCAAGG-30 (forward primer), 50-TGGATGCAGGGATGATGTTC-30 (reverse primer).
(C) Immunohistological analysis of tamoxifen-induced and control mice demonstrates the maintained expression of the podocyte marker protein
synaptopodin whereas Wt1 and nephrin are repressed on the protein level after induction of Pax2. Note the reduced complexity/size of glomeruli
(arrows) after PAX2 expression. Scale bars equal 100 mm. Immunohistological analyses were performed as described [30] with the following
antibodies: anti-Synaptopodin (65194, Progen), anti-Wt1 from mouse (F-6, sc7385, Santa Cruz Biotechnology), anti-Nephrin from guinea pig
(GP-N2, Progen). Sections were counterstained with hematoxylin (Sigma).
(D) Transient transfection experiments in HeLa cells by means of a Wt1 promoter reporter construct (n = 6) [33]. Cotransfection of TLE4 (Grg4) [3]
suppressed Pax2b-specific activation of the Wt1 promoter in a dose-dependent fashion. pGl2basic served as an empty vector control. Cell cul-
ture, transient transfections, and reporter assays were performed as described [31]. (For experimental details, see Supplemental Experimental
Procedures.)
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798Figure 4. Functional and Molecular Analyses in Tamoxifen-Inducible Animals with and without ACE Inhibition
(A) Treatment of Pax2-expressing mice with enalapril (3 mg/kg/day) reverted urinary protein excretion to normal levels.
(B) Enalapril-treatment was associated with cellular proliferation already after 3 weeks as revealed by immunostaining for PCNA (anti-PCNA
antibody from mouse, sc-56, Santa Cruz Biotechnology). Scale bars equal 100 mm.
(C) Real-time PCR analysis of tamoxifen (white bar, n = 11) and tamoxifen+enalapril-treated mice (black bars, n = 7) demonstrated an increase in
Pax2, AT1A, and nephrin expression. In contrast, no significant change in Wt1 expression levels could be detected.To understand the molecular pathway leading to glo-
merular disease, we next analyzed the expression of
Gdnf and the frizzled related protein Sfrp2, two genes
that have been proposed to be transcriptional targets
of Pax2 [15, 16]. Real-time RT-PCR analysis 3 weeks
after tamoxifen injection detected no statistically signif-
icant difference between induced animals and controls
(Figure 3B). As controls for all real-time RT-PCR analy-
sis, double-transgenic mice injected with vehicle and
single Z/Pax2 transgenic animals injected in parallel
with tamoxifen were used. Since no significant differ-
ences between these two control groups could be de-
tected for any of the investigated parameters, they
were pooled for the final statistical comparison to the in-
duced animals. The lack of upregulation of Gdnf and
Sfrp2 in the induced animals suggests that at least in po-
docytes, expression of Pax2 is not sufficient to activate
these genes (Figure 3B). We next addressed whether the
expression of podocyte-specific markers was altered
after Pax2 induction. Wt1 is a transcription factor regu-
lating several key proteins of the podocyte including
nephrin [17] and podocalyxin [18], and reduced levels
of Wt1 have been shown to cause glomerular diseases
[8]. Strikingly, RT-PCR analyses and immunohisto-
chemistry demonstrated a dramatic reduction of both
Wt1 and nephrin in tamoxifen-induced mice (Figures
3B and 3C), whereas expressions of podocalyxin (Fig-
ure 3B) and synaptopodin (Figure 3C) were not signifi-
cantly changed, pointing toward a direct regulation of
Wt1 and nephrin in our model instead of being solely a
reflection of glomerular damage. Cotransfection assaysin HeLa cells showed that Pax2 weakly activates rather
than represses a nephrin promoter construct [19], sug-
gesting that repression of nephrin is not a direct effect
of the upregulation of Pax2. Given the phenotype of
nephrin mutations in man and mouse [20, 21], we pro-
pose that the severe reduction in the expression of this
gene in our mouse model contributes significantly to
the observed defects, thus once again underlining its
importance for the formation of the filtration barrier. Fur-
thermore, expression of the At1 receptor, which is de-
regulated in human kidney diseases [22], was reduced
in tamoxifen-induced mice. Since in a cell line with in-
ducible WT1 expression, mRNA for the AT1 receptor
was increased by a factor of 2.0 6 0.3 (n = 5, p < 0.05)
upon WT1 induction (data not shown), it is likely that
also this molecule directly depends on Wt1, pointing
again at a role of Wt1 as a key regulator for glomerular
disease.
Earlier publications have described Wt1 as a direct
target of the transcriptional activator Pax2 [23] in differ-
ent nonkidney cell lines, and as such we could have
expected an increase in Wt1 rather than the observed
dramatic reduction in animals ectopically expressing
Pax2. Several Pax proteins are able to interact with
groucho (TLE) family members [3, 24], which convert
these proteins from transcriptional activators to repres-
sors. In the kidney, TLE4 has been described to be ex-
pressed specifically within differentiated podocytes
[24], and TLE4 mRNA levels did not differ between ta-
moxifen-induced animals and controls (data not shown).
To test whether TLE4 can suppress Pax2-dependent
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799activation of Wt1, we performed cotransfection experi-
ments with the Wt1 promoter and a Pax2 expression
construct in the presence or absence of TLE4 in HeLa
cells. As expected from the literature [23], cotransfec-
tion of Pax2 with the Wt1 reporter construct led to mod-
erate activation of the Wt1 promoter. This activation
could be suppressed in a dose-dependent fashion in
the presence of TLE4 (Figure 3C). These in vitro data
might at least in part explain the dramatic downregula-
tion of the Wt1 gene in our tamoxifen-induced mouse
model in vivo. This regulatory pathway might be also
important for human glomerular diseases, where Pax2
expression has been described in adult podocytes [6].
Glomerular diseases in human patients are typically
treated with drugs interfering with the renin-angiotensin
system [25]. We therefore tested whether our mouse
model would respond to the angiotensin converting en-
zyme (ACE) inhibitor enalapril at a dose (3 mg/kg/day)
that has no significant effect on systemic blood pressure
[26], although we can not exclude that this dose has
a blood pressure lowering effect in our diseased mice.
We followed protein excretion as a diagnostic marker
for a total of 3 weeks. Untreated mice suffered from
severe proteinuria and only 5 out of 23 mice survived
during the observation period. In contrast, enalapril
treatment resulted in a significant reduction of excreted
protein levels (Figure 4A) and a dramatically increased
survival (9 out of 11). These improvements are unlikely
to be due to a simple stabilization of the vascular com-
ponent of the glomerulus, since VEGF-A and angiopoie-
tin 1 levels were not significantly different in treated ver-
sus untreated animals (data not shown). Angiotensin II in
the mouse acts primarily through the angiotensin recep-
tor At1a, and we hypothesized that enalapril treatment
may result in a molecular response in the expression
of the receptor. Indeed, real-time RT-PCR analysis dem-
onstrated a significant increase ofAt1amRNA, probably
reflecting a physiological feedback mechanism. Also,
nephrin expression was higher in enalapril-treated ani-
mals when compared to controls, as it has been already
reported for other models of glomerular disease treated
with ACE inhibitors [27], whereas Wt1 showed no signif-
icant change (Figure 4C). Surprisingly, Pax2 expression
was increased in enalapril-treated animals when com-
pared to controls (Figure 4C). This enhanced expression
could be localized by immunohistochemistry to glomer-
ular, tubular, and collecting duct cells (data not shown)
and might at least in part be due to proliferation of these
cells already after 3 weeks of tamoxifen induction com-
bined with enalapril treatment (Figure 4B). Taken to-
gether, these data demonstrate that ACE inhibitors ex-
hibit a curative effect also in our mouse model, which
at least in part could be attributed to partial normaliza-
tion of the expression of Wt1-dependent genes, al-
though we cannot exclude that other yet unidentified
mechanisms might play a role.
In summary, we have generated a unique genetically
inducible model for renal disease, which is informative
for successive events and molecular alterations in the
development of glomerular disease. Our data provide
evidence that ectopic expression of PAX2 in glomerular
podocytes represents a major factor for the develop-
ment of glomerular disease. In contrast to the normal
developmental regulation, the activation of Pax2 inmature podocytes seems to repress Wt1 and conse-
quently leads to the repression of the crucial structural
protein nephrin. Molecular analysis of ACE inhibitor-
treated animals shows that expression of podocyte-
specific genes such as nephrin can be increased
through mechanisms different from the developmental
regulation.
Supplemental Data
Supplemental Data include four figures and Supplemental Experi-
mental Procedures and can be found with this article online at
http://www.current-biology.com/cgi/content/full/16/8/793/DC1/.
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